

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rearguard 60 mg/ml Cutaneous Solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:

Each ml contains:
60 mg cyromazine.

Excipients:

Qualitative composition of excipients and other constituents
Methyl parahydroxybenzoate
Ethyl parahydroxybenzoate
Propyl parahydroxybenzoate
Lactic acid edible 80
Acetic acid glacial
Propylene glycol
Macrogol cetostearyl ether
Silicone emulsion
Water de-ionised

Clear, pale yellow solution

3. CLINICAL INFORMATION

3.1 Target species

Rabbit

3.2 Indications for use for each target species

For the prevention of blowfly strike (*Lucilia sericata*) in domestic rabbits for up to 10 weeks after dosing.

3.3 Contraindications

Not to be used on rabbits less than 10 weeks of age. Do not apply to broken skin.

3.4 Special warnings

If the rabbit is continually attractive to flies, this may be due to an underlying disease e.g. diarrhoea or incontinence, or a lack of hygiene within its housing. In such cases further advice should be sought from your veterinary surgeon.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Care should be taken in the treatment of old, sick or debilitated rabbits.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands and exposed skin after use.

Wash splashes from skin and eyes immediately.

Do not smoke whilst using the veterinary medicinal product.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Rare (1 to 10 animals / 10,000 animals treated):	Anorexia ¹
---	-----------------------

¹ Transient; lasts 24-48 hours following treatment

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and fertility:

Not to be used in pregnant or breeding females.

3.8 Interaction with other medicinal products and other forms of interaction

None known

3.9 Administration routes and dosage

The veterinary medicinal product comes supplied ready-to-use in a bottle with built-in applicator sponge. Gently depress the sponge to break the valve before applying.

Apply the veterinary medicinal product using the sponge applicator, ensuring that the rabbit's fur is thoroughly wetted with the solution from the middle of the back to the tip of

the tail. Special attention should be paid to the areas under the tail and between the back legs. Contents of the bottle is a single application. Do not allow the veterinary medicinal product to run off the animal.

Rabbits should be first treated in early summer before any flies are seen. The veterinary medicinal product will not kill adult maggots but works by preventing any eggs laid by flies developing.

Rabbits should be treated at 8-10 week intervals under conditions of repeated blowfly challenge. Bathing or washing the rabbit after application may result in a reduction of efficacy.

In cases of existing flystrike, adult maggots should be removed by mechanical means and appropriate supportive treatment given. The veterinary medicinal product should then be applied to the fur to prevent development of new larvae and re-strike.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not to be used on rabbits intended for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QP53AX

4.2 Pharmacodynamics

Cyromazine is an insect growth regulator. It is not pharmacologically active in mammals.

4.3 Pharmacokinetics

Dermal absorption rate: a maximum of 10% of dose over 8 hours. Cyromazine is rapidly excreted in mammals and birds.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known

5.2 Shelf life

Shelf life of veterinary medicinal product as packaged for sale: 3 years

5.3 Special precautions for storage

Do not store above 25°C.
Protect from frost.
Protect from direct sunlight.
Shake the container before use.
Store in tightly closed original container.
Store away from food and drink.

5.4 Nature and composition of immediate packaging

25 ml HDPE bottle with LDPE valve and LDPE sponge applicator, closed with a LDPE push cap.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Elanco GmbH

7. MARKETING AUTHORISATION NUMBER

Vm 52127/5069

8. DATE OF FIRST AUTHORISATION

20 June 2002

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

May 2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product not subject to prescription.

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Revised: May 2026
AN: 03872/2025

Approved 20 May 2026
Gavin Hall